(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Occupational Diseases D009784 42 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Arthritis D001168 41 associated lipids
Nervous System Diseases D009422 37 associated lipids
Acne Vulgaris D000152 35 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Micronuclei, Chromosome-Defective D048629 33 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Brain Diseases D001927 27 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Rouleau I et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. 2013 Vaccine pmid:24144473
Iorio AM et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. 2003 Vaccine pmid:12922092
Javelle E et al. Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. 2011 Vaccine pmid:21172376
Esposito S et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. 2011 Vaccine pmid:21199699
Esposito S et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. 2010 Vaccine pmid:20888873
O'Hagan DT et al. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. 2004 Vaccine pmid:15542189
Pellegrini M et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. 2009 Vaccine pmid:19751689
Forrest HL et al. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. 2009 Vaccine pmid:19406182
Camilloni B et al. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. 2009 Vaccine pmid:19410623
Byars NE and Allison AC Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. 1987 Vaccine pmid:3499713
Phillips CJ et al. Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. 2009 Vaccine pmid:19379786
Singh M et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. 1998 Vaccine pmid:9795387
Ansaldi F et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. 2010 Vaccine pmid:20433807
Carmona A et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. 2010 Vaccine pmid:20600478
Higgins DA et al. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. 1996 Vaccine pmid:8782343
Minutello M et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. 1999 Vaccine pmid:9987141
Hilgers LA et al. Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. 1999 Vaccine pmid:9987157
Podda A The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. 2001 Vaccine pmid:11257408
Fabbiani M et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. 2011 Vaccine pmid:21349364
Dell'Era L et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. 2012 Vaccine pmid:22138210
Yu S et al. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. 2012 Vaccine pmid:22709954
Dey AK et al. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. 2012 Vaccine pmid:22366638
Brito LA et al. An alternative renewable source of squalene for use in emulsion adjuvants. 2011 Vaccine pmid:21723355
Puig-Barberà J et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. 2007 Vaccine pmid:17889411
Guillon C et al. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. 2007 Vaccine pmid:17904700
Chandramouli S et al. Generation of a parvovirus B19 vaccine candidate. 2013 Vaccine pmid:23827313
Yang WH et al. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. 2013 Vaccine pmid:23856331
Madhun AS et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. 2010 Vaccine pmid:21034828
Wack A et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. 2008 Vaccine pmid:18162266
Nielsen AB et al. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. 2012 Vaccine pmid:23036498
Garcia-Sicilia J et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. 2011 Vaccine pmid:21504774
Dediukhina EG and Eroshin VK [Hydrocarbon biosynthesis by microorganisms]. 1973 Nov-Dec Usp Sovrem Biol pmid:4593530
PerederiÄ­ OF and Morozova RP [Squalene and sterols of rat stomach tissue and the effect of acetylsalicylic acid on their content]. 1978 Nov-Dec Ukr. Biokhim. Zh. pmid:749299
Morozova RP et al. [Separation of lipid extract from animal blood and tissues and isolation of squalene and sterols from it]. 1982 Jul-Aug Ukr. Biokhim. Zh. pmid:7135500
Vendt VP [Studies in the field of chemistry, biochemistry and photobiochemistry of sterols]. 1975 Sep-Oct Ukr Biokhim Zh pmid:1105921
Sanina OL and Datsenko ZM [Sterol composition of sarcolemma in normal rabbits and in experimental muscular dystrophy]. 1975 Nov-Dec Ukr Biokhim Zh pmid:1202710
Ihara T [Evaluation of alum-adjuvanted whole virus influenza vaccine and future aspects of influenza A (H1N1) 2009 vaccine]. 2010 Uirusu pmid:20848866
Laursen AB [Dangerous adjuvant in swine influenza vaccine]. 2009 Ugeskr. Laeg. pmid:19866499
Bruun Laursen A [Catastrophic consequences of Pandemrix swine flu vaccine containing squalene]. 2013 Ugeskr. Laeg. pmid:23833781
Mølbak K [Squalene unlikely sinner]. 2013 Ugeskr. Laeg. pmid:23833782
Moebius FF et al. Genetic defects in postsqualene cholesterol biosynthesis. 2000 Trends Endocrinol. Metab. pmid:10707051
Siirtola A et al. Cholesterol absorption and synthesis in pediatric kidney, liver, and heart transplant recipients. 2006 Transplantation pmid:16477216
Gylling H et al. Cholesterol synthesis prevails over absorption in metabolic syndrome. 2007 Transl Res pmid:17543849
Johnson WS Nonenzymic biogenetic-like olefinic cyclizations. 1967 Trans N Y Acad Sci pmid:5237390
Sunthornandh P and Ratanabanangkoon K A comparative study of three vehicles on antibody responses against elapid snake neurotoxin immunogens. 1994 Toxicon pmid:8079368
Kuroda Y et al. Distinctive patterns of autoimmune response induced by different types of mineral oil. 2004 Toxicol. Sci. pmid:14718649
Flint OP et al. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. 1997 Toxicol. Appl. Pharmacol. pmid:9221828
Uchino T et al. Potent protecting effects of Catuaba (Anemopaegma mirandum) extracts against hydroperoxide-induced cytotoxicity. 2004 Toxicol In Vitro pmid:15046771
Yockel S and Schatz GC Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. 2012 Top Curr Chem pmid:21506003
Hayakawa K and Matsuo I Effects of PUVA therapy on skin surface lipids: skin surface lipid peroxidation in psoriasis vulgaris and its biological significance. 1986 Tokai J. Exp. Clin. Med. pmid:3672560